GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Cash Conversion Cycle

Guided Therapeutics (Guided Therapeutics) Cash Conversion Cycle : -61,783.85 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Guided Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 106.46.
Guided Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 28835.
Guided Therapeutics's Days Payable for the three months ended in Mar. 2024 was 90725.31.
Therefore, Guided Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was -61,783.85.


Guided Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Guided Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guided Therapeutics Cash Conversion Cycle Chart

Guided Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15,208.62 66.20 -11,235.07 -7,279.73 -9,006.59

Guided Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,763.04 -4,435.99 -35,587.50 -8,326.56 -61,783.85

Competitive Comparison of Guided Therapeutics's Cash Conversion Cycle

For the Medical Devices subindustry, Guided Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Cash Conversion Cycle falls into.



Guided Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Guided Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=24.21+3473.39-12504.19
=-9,006.59

Guided Therapeutics's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=106.46+28835-90725.31
=-61,783.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guided Therapeutics  (OTCPK:GTHP) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Guided Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Guided Therapeutics (Guided Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
John E Imhoff director, 10 percent owner P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic director 349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg director 2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff 10 percent owner 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright officer: Chief Executive Officer 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp. 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock director 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff director C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen director P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot officer: VP of R & D 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines